DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...

The Nifty Pharma index closed on a note on Wednesday. Shares of Dr. Reddy's Laboratories Ltd.(up 1.43 per cent) ended the day ...

Dr Reddy's Laboratories Limited has announced the sale of its step-down wholly owned subsidiary, Dr Reddy's Laboratories ...

The S&P BSE Sensex was down 141.64 points to 78,057.47 at 10:09 am, while the NSE Nifty50 was trading 42.60 points lower at ...

Foreign institutional investors (FIIs) remained net sellers, offloading equities worth Rs 1,491.46 crore on January 7, while ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Stocks like Tata Steel, Dr Reddy’s Laboratories, WPIL, Rail Vikas Nigam, Mahindra and Mahindra, Mankind Pharma, CESC, ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.01% to 1,350.75 Indian rupees Tuesday, on what proved to be an all ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.16% to 1,350.65 Indian rupees Monday, on what proved to be an ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.